COMPANY

Curi Bio, Inc.

HQ: Seattle, WA source · curibio.com ↗ · West Coast

Location: Seattle, WA · source · Oct 14, 2026

Profile checked Oct 10, 2026

26NIH grants

Raises and deals from press releases

Raise Series B · $10M · announced Dec 2, 2025 Company release ↗
Source quote
- Dec 2, 2025 · Company release ↗
  “SEATTLE, WA – December 2, 2025 [ Originally posted on BusinessWire ] – Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round”

Raises announced in these releases: $10M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Dec 2, 2025 Raise Series B · $10M source ↗
Jan 10, 2025 Grant Government grant — SBIR: $901,175 (annual award, as published), announced Jan 10, 2025. Agency: NIH/NCATS. Source: government award database. source ↗
Nov 13, 2024 Grant Government grant — SBIR: $1.15M (annual award, as published), announced Nov 13, 2024. Agency: NIH/NCATS. Source: government award database. source ↗

Funding

Last 2 years.

Jan 10, 2025 Government grant — SBIR: $901,175 (annual award, as published), announced Jan 10, 2025. Agency: NIH/NCATS. Source: government award database. source ↗
Nov 13, 2024 Government grant — SBIR: $1.15M (annual award, as published), announced Nov 13, 2024. Agency: NIH/NCATS. Source: government award database. source ↗

NIH awards 26

Annual award amounts. Total $9.9M.

Dec 18, 2023 NIH award 4U44TR004795-02 FY2024: $910,019 awarded for that fiscal year; activity U44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. High-Throughput NMJ Assay for Botox Potency S source ↗
Nov 8, 2023 NIH award 4R44TR004557-02 FY2024: $832,365 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. A cross-species preclinical platform to enhan source ↗
Aug 1, 2023 NIH award 1U44TR004795-01 FY2023: $275,766 awarded for that fiscal year; activity U44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. High-Throughput NMJ Assay for Botox Potency S source ↗
May 31, 2023 NIH award 1R44TR004557-01 FY2023: $324,648 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. A cross-species preclinical platform to enhan source ↗
Nov 15, 2022 NIH award 3R44HL151094-03S2 FY2023: $169,156 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Predictive assessment of acute and chronic source ↗
Aug 31, 2022 NIH award 3R44HL151094-03S1 FY2022: $242,088 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Predictive assessment of acute and chronic source ↗
Aug 30, 2022 NIH award 5R44HL151094-03 FY2022: $750,000 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Predictive assessment of acute and chronic ca source ↗
Mar 6, 2022 NIH award 3R44HL151094-02S1 FY2022: $123,144 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Predictive assessment of acute and chronic source ↗
Sep 2, 2021 NIH award 4R44HL151094-02 FY2021: $750,000 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Predictive assessment of acute and chronic ca source ↗
Jul 28, 2021 NIH award 3R44HL149566-03S1 FY2021: $179,200 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Bioengineering Mature Human Pluripotent Ste source ↗
Jul 27, 2021 NIH award 5R44HL149566-03 FY2021: $745,488 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Bioengineering Mature Human Pluripotent Stem source ↗
Mar 19, 2021 NIH award 3R44HL149566-02S1 FY2021: $69,068 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Bioengineering Mature Human Pluripotent Stem source ↗
Sep 11, 2020 NIH award 1R43HL154928-01 FY2020: $252,131 awarded for that fiscal year; activity R43 (SBIR); PI FINE, ELI; recipient as written: CURI BIO INC, SEATTLE, WA. Cryopreserving Stem Cell-Derived Cardiomyocytes in Ready-to source ↗
Jul 27, 2020 NIH award 1R44HL151094-01 FY2020: $225,000 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Predictive assessment of acute and chronic ca source ↗
Jul 15, 2020 NIH award 1R43HL150971-01A1 FY2020: $252,131 awarded for that fiscal year; activity R43 (SBIR); PI JHA, RAJNEESH; recipient as written: CURI BIO INC, SEATTLE, WA. Maturation of stem cell-derived cardiomyocytes using source ↗
Jun 5, 2020 NIH award 4R44HL149566-02 FY2020: $750,000 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Bioengineering Mature Human Pluripotent Stem source ↗
Sep 14, 2019 NIH award 1R43EB029311-01 FY2019: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Multiplexed quantitative measurements of fiel source ↗
Sep 13, 2019 NIH award 1R43EB028183-01A1 FY2019: $221,713 awarded for that fiscal year; activity R43 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Low-cost, Roll-to-Roll Manufacturing of Nan source ↗
Aug 16, 2019 NIH award 1R44HL149566-01 FY2019: $225,000 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. Bioengineering Mature Human Pluripotent Stem source ↗
Jul 24, 2019 NIH award 3R44HL131169-03S2 FY2019: $129,050 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. High-throughput nanoMEA-based Proarrhythmia source ↗
Jul 22, 2019 NIH award 3R44HL131169-03S1 FY2019: $123,510 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. High-throughput nanoMEA-based Proarrhythmia source ↗
Jul 11, 2019 NIH award 5R44HL131169-03 FY2019: $747,868 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. High-throughput nanoMEA-based Proarrhythmia A source ↗
May 17, 2019 NIH award 1R43HL146043-01A1 FY2019: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. A Combinatorial Bioreactor for Electromecha source ↗
Sep 21, 2018 NIH award 2R44HL131169-02A1 FY2018: $748,435 awarded for that fiscal year; activity R44 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. High-throughput nanoMEA-based Proarrhythmia source ↗
Sep 21, 2017 NIH award 1R43CA221659-01 FY2017: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI GEISSE, NICHOLAS ANDREW; recipient as written: CURI BIO INC, SEATTLE, WA. A Nanopatterned Interdigitated Electrode Arra source ↗
Aug 30, 2016 NIH award 1R43HL131169-01 FY2016: $214,000 awarded for that fiscal year; activity R43 (SBIR); PI SMITH, ALEC SIMON TULLOCH; recipient as written: CURI BIO INC, SEATTLE, WA. High-throughput nanoMEA-based Proarrhythmia source ↗